Loading…
NeuroSense Therapeutics Ltd. is projected to rise to $0.7727 by 2027, a +7% move from its current price of $0.7199. NRSN is currently trading below its 50-day average (a bearish sign). Technical indicators currently lean strong sell.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 13 | $0.70 | $0.7205 | $0.7416 | +0.08% |
| Jul 14 | $0.6922 | $0.7211 | $0.7512 | +0.16% |
| Jul 15 | $0.6864 | $0.7217 | $0.7588 | +0.25% |
| Jul 16 | $0.6817 | $0.7223 | $0.7653 | +0.33% |
| Jul 17 | $0.6776 | $0.7229 | $0.7712 | +0.41% |
| Jul 18 | $0.674 | $0.7235 | $0.7766 | +0.49% |
| Jul 19 | $0.6707 | $0.7241 | $0.7816 | +0.58% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $0.6707 | $0.7241 | $0.7816 | +0.58% |
| Week 2 | $0.6535 | $0.7282 | $0.8115 | +1.16% |
| Week 3 | $0.6415 | $0.7324 | $0.8362 | +1.74% |
| Week 4 | $0.6321 | $0.7367 | $0.8585 | +2.33% |
| Week 5 | $0.6244 | $0.7409 | $0.8792 | +2.92% |
| Week 6 | $0.6178 | $0.7452 | $0.8988 | +3.51% |
| Week 7 | $0.6121 | $0.7495 | $0.9177 | +4.11% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
NeuroSense Therapeutics Ltd. is a clinical-stage biotechnology company focused on discovering and developing treatments for neurodegenerative diseases in the United States and internationally. Its lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease.
NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. The preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease.
NeuroSense Therapeutics Ltd. (Healthcare) currently trades at $0.7099 per share. The market capitalization is $25.63M and the rank is 4563.
The stock sits in the Healthcare sector with a current price of $0.7099 and a market cap of $25.63M, ranking 4563 among peers. The forecasted price path suggests upside potential over the horizon, with higher average prices projected in later years.
A major floor 18.6% below — a decisive break under it would weaken the trend.
The nearest floor, 4.6% below — buyers have tended to step in here.
The nearest ceiling, 19.5% above — a clean break opens room to run.
A major ceiling 32.0% above — clearing it would confirm fresh momentum.
Key NRSN support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of NRSN market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $0.7124 | Buy | $0.7191 | Buy |
| MA 10 | $0.718 | Buy | $0.7223 | Sell |
| MA 20 | $0.7313 | Sell | $0.735 | Sell |
| MA 50 | $0.7874 | Sell | $0.7639 | Sell |
| MA 100 | $0.7913 | Sell | $0.8105 | Sell |
| MA 200 | $0.913 | Sell | $0.9132 | Sell |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 46.72 | Neutral |
| Stoch RSI (14) | 58.60 | Neutral |
| CCI (20) | -5.86 | Neutral |
| Williams %R (14) | -64.52 | Info |
| MACD (12,26,9) | 0.00 | Buy |
| ROC (12) | -5.08 | Sell |
| Bollinger %B (20,2) | 0.48 | Neutral |
| Stochastic %K (14) | 35.48 | Neutral |
| TRIX (15) | -0.36 | Sell |
| Awesome (5,34) | -0.05 | Sell |
| Ultimate (7,14,28) | 46.18 | Neutral |
| Momentum (10) | -0.03 | Sell |
| Aroon Osc (25) | 12.00 | Buy |
| Hull MA (9) | 0.72 | Buy |
| ADX (14) | 13.64 | Neutral |
| ATR (14) | 0.02 | Info |
The near-term technical picture is NEUTRAL.
RSI (14) is 40, signaling modest downside momentum relative to overbought/oversold thresholds. The 50-day simple moving average sits at $0.7898 and the 200-day simple moving average sits at $0.9323, indicating price action that is trading below both key averages.
Support is identified at $0.687 and resistance at $0.895. The 30-day price range spans from $0.5604 to $0.8992. Annualized volatility stands at 70%, underscoring elevated but manageable risk levels in the near term.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $0.687 | $0.7199 | $0.9977 | 0% | Neutral | |
| $0.6117 | $0.7727 | $1.03 | +7% | Neutral | |
| $0.6804 | $0.8854 | $1.23 | +23% | Bullish | |
| $0.8931 | $1.19 | $1.71 | +65% | Bullish | |
| $0.898 | $1.22 | $1.80 | +70% | Bullish | |
| $0.9159 | $1.27 | $1.92 | +77% | Bullish | |
| $0.9647 | $1.37 | $2.10 | +90% | Bullish | |
| $0.9125 | $1.32 | $2.06 | +83% | Bullish | |
| $1.02 | $1.49 | $2.37 | +108% | Bullish | |
| $1.17 | $1.74 | $2.81 | +142% | Bullish | |
| $1.40 | $2.24 | $3.86 | +211% | Bullish | |
| $2.83 | $5.14 | $9.71 | +614% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $0.687 | $0.7199 | $0.8767 | +0.00% |
| August 2026 | $0.6527 | $0.7717 | $0.938 | +7.20% |
| September 2026 | $0.6514 | $0.7759 | $0.9542 | +0.54% |
| October 2026 | $0.638 | $0.7648 | $0.9498 | -1.43% |
| November 2026 | $0.6496 | $0.7829 | $0.9803 | +2.37% |
| December 2026 | $0.6528 | $0.7908 | $0.9977 | +1.01% |
Click any year to see its month-by-month NRSN forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, NRSN could reach as high as $0.9977, with a base case around $0.7199 and support toward $0.687 — roughly 0% from $0.7199. Price action looks broadly range-bound.
Expect NRSN to range from $0.6117 to $1.03 through 2027. The $0.7727 average target implies a +7% move from current prices. That is up +7% on the projected 2026 average. A consolidation phase looks the most probable path here.
The NRSN price prediction for 2028 points to an average of $0.8854 (low $0.6804, high $1.23) — a potential gain of +23% on today's $0.7199. Momentum favours further upside here.
In 2029, NRSN is projected to trade between $0.8931 and $1.71, averaging $1.19 — a potential gain of +65% from today's $0.7199. That is up +35% on the projected 2028 average. Buyers look set to stay in control over this stretch.
NeuroSense Therapeutics Ltd.'s 2030 outlook centres on $1.22, within a $0.898 to $1.80 range. That is up +3% on the projected 2029 average. That marks a +70% change versus current levels. Momentum favours further upside here.
By 2031, NRSN could reach as high as $1.92, with a base case around $1.27 and support toward $0.9159 — roughly +77% from $0.7199. Buyers look set to stay in control over this stretch.
Expect NRSN to range from $0.9647 to $2.10 through 2032. The $1.37 average target implies a +90% move from current prices. That is up +7% on the projected 2031 average. Momentum favours further upside here.
The NRSN price prediction for 2033 points to an average of $1.32 (low $0.9125, high $2.06) — a potential gain of +83% on today's $0.7199. Buyers look set to stay in control over this stretch.
In 2034, NRSN is projected to trade between $1.02 and $2.37, averaging $1.49 — a potential gain of +108% from today's $0.7199. That is up +14% on the projected 2033 average. Momentum favours further upside here.
NeuroSense Therapeutics Ltd.'s 2035 outlook centres on $1.74, within a $1.17 to $2.81 range. That is up +17% on the projected 2034 average. That marks a +142% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, NRSN could reach as high as $3.86, with a base case around $2.24 and support toward $1.40 — roughly +211% from $0.7199. Momentum favours further upside here.
Expect NRSN to range from $2.83 to $9.71 through 2050. The $5.14 average target implies a +614% move from current prices. That is up +129% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in NRSN today (≈ 1,389.081817 NRSN) could be worth
$7,137.49
+$6,137.49 (+614%) by 2050 · US Dollar
Based on the average projected NRSN price of $5.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in NRSNwould be worth at today's price.
$1,000 invested in NRSN on Jul 10, 2025 (≈ 473.933673 NRSN) would be worth
$341.18
-$658.82 (-65.9%) today · 0.34× · US Dollar
Based on a NRSN entry price of $2.11 vs. today's $0.7199.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $0.708 | $1,016.81 | +1.7% |
| 1 month ago | $0.731 | $984.82 | -1.5% |
| 3 months ago | $0.7 | $1,028.43 | +2.8% |
| 6 months ago | $1.03 | $698.93 | -30.1% |
| 1 year ago | $2.11 | $341.18 | -65.9% |
| All time (4.6y) ago | $4.04 | $178.19 | -82.2% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our NRSN forecast.
Our base-case forecast reaches $1.40 around 2034.
Implied market cap at $1.40: $50.54M
The multi-year forecast shows a gradual rise in average prices with bullish momentum building into the late 2020s and extending through 2050.
For 2026, the average price is projected at $0.7099 with a min of $0.687 and a max of $1.01, and a 0% ROI under NEUTRAL sentiment. In 2027, the average is $0.7522, with a min of $0.5806, max $1.04, and a 6% ROI under NEUTRAL sentiment. From 2028 onward, the outlook becomes BULLISH, with 2028 avg $0.9087 (min $0.6755, max $1.32) and ROI 28%; 2029 avg $1.25 (min $0.9015, max $1.88) with ROI 76.3%.
2030 follows at avg $1.27 (min $0.8863, max $1.96) and ROI 78.3%, continuing bullish momentum through 2031 (avg $1.33) and 2032 (avg $1.41), with ROIs of 86.8% and 98.3% respectively.
2033 through 2050 continues a bullish trajectory: 2033 avg $1.32 (min $0.8599, max $2.19, ROI 86.1%); 2034 avg $1.55 (min $0.9887, max $2.63, ROI 118.7%); 2035 avg $1.83 (min $1.14, max $3.16, ROI 158.2%). By 2040 the average is $2.37 (min $1.34, max $4.40, ROI 233.8%), and by 2050 the average is $5.48 (min $2.60, max $11.32, ROI 672.3%), with sentiment remaining BULLISH.
Tap a question to reveal the answer.
Avg $1.27; Min $0.8863; Max $1.96; ROI 78.3%; sentiment BULLISH.
The forecast shows rising averages and positive ROIs over time (e.g., 2027 6%, 2028 28%, 2029 76.3%, 2030 78.3%, 2031 86.8%, 2032 98.3%, 2040 233.8%, 2050 672.3%), with bullish sentiment from 2028 onward. These are estimates, not guarantees.
Yes. The forecast shows an average price of $1.25 in 2029 and $1.27 in 2030, with subsequent years staying above $1 (e.g., 2031: $1.33; 2032: $1.41).
Current price is $0.7099 and market cap is $25.63M.
Avg $5.48; Min $2.60; Max $11.32; ROI 672.3%; sentiment BULLISH.
NeuroSense Therapeutics Ltd. Community Discussion
0Share your NeuroSense Therapeutics Ltd. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.